Post-earnings recap
Reported
Thu, Aug 6, 2026
EPS actual
$-0.90
EPS est.
$-0.70
EPS surprise
-28.57%
1-day move
+3.36%
CG Oncology's earnings report showed a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock reacted positively, increasing by 3.36%. This could indicate that investors are looking beyond the current losses, possibly anticipating future developments or improvements.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.90 | $-0.82 | -28.57% |
| Revenue | — | $1M | — |
No transcript is on record for the earnings call, so the analysis is based solely on numerical results.
CG Oncology, Inc. is a biotechnology company focused on developing innovative therapies for cancer treatment. Operating in the health care sector, it plays a crucial role in addressing unmet medical needs in oncology, which is a significant area of concern for patients and healthcare providers alike.
Last quarter
In Q1-2026, CG Oncology reported an EPS of -$0.71, which was worse than the expected -$0.58. The stock reacted positively, increasing by 0.64% the following day.
Management promises and guidance
EPS beat streak
0Q
EPS beat rate
25%
Avg EPS surprise
-31.88%
Avg 1-day reaction
+1.97%
Analysts are anticipating a challenging quarter for CG Oncology, with expectations of a wider loss compared to previous estimates. The consensus is cautious, reflecting concerns about revenue generation.
Bull case
If CG Oncology can exceed EPS expectations and show significant revenue growth, it may signal strong demand for its therapies and lead to a positive market reaction.
Bear case
A larger-than-expected loss or disappointing revenue could reinforce concerns about the company's growth prospects and lead to a negative reaction in the stock.
Key metrics to watch
EPS
-$0.82Earnings per share (EPS) is a key indicator of the company's profitability and financial health. Investors will closely watch this figure to gauge performance against expectations.
Revenue
$1MRevenue figures provide insight into the company's sales performance and market demand for its products. A strong revenue number could indicate growing acceptance of its therapies.
The print will turn on these.
Q1
Will the EPS come in better than the consensus estimate of -$0.82?
A better-than-expected EPS could indicate improved operational efficiency and market acceptance of CG Oncology's products.
Q2
What revenue figures will CG Oncology report, and how do they compare to the $1M consensus?
Revenue performance will be critical in assessing the company's growth trajectory and market demand for its therapies.
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Why consensus could be wrong
The Street may be underestimating the potential for CG Oncology to surprise on revenue, given recent advancements in their clinical trials that have not been fully factored into estimates.
Supporting evidence
The company's recent partnerships could lead to increased sales not reflected in current revenue expectations.
Historical trends show that CG Oncology has occasionally outperformed revenue estimates despite prior misses.
Key risk
If revenue comes in significantly above $1M, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
This quarter's performance is pivotal as it will reflect the company's ability to navigate challenges and capitalize on growth opportunities.
Bull confirmed if
An EPS of -$0.66 or better, coupled with revenue exceeding $1M, would confirm the bull case.
Bear confirmed if
An EPS worse than -$0.96 and revenue below $1M would confirm the bear case.
What the market is pricing for the move.
Implied Move
±36.98%
Historical Avg
±4.6%
The options market is pricing in a significant potential move in the stock, indicating high uncertainty around the upcoming earnings report.
Options are pricing ±37.0% while CGON has averaged ±4.6% over the last 8 prints — setup is pricing rich.
ATM IV
0.9%
30d HV
51.9%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If CG Oncology beats expectations, history suggests the stock could rise by around 0.1% on the day, confirming positive market sentiment.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further guidance.
Miss
Should the company miss estimates, history indicates an average decline of about 0.79%, reflecting investor disappointment.
The lines on the call that would change the story.